1177 Avenue of the Americas
5th floor
New York, NY 10036
United States
332 216 1147
https://sunshinebiopharma.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 44
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Camille Sebaaly | CFO & Secretary | 695k | N/A | 1959 |
Dr. Abderrazzak Merzouki | Chief Science Officer & Director | 340k | N/A | 1964 |
Dr. Steve N. Slilaty Ph.D. | CEO, President & Chairman | 430k | N/A | 1952 |
Mr. Marc Beaudoin | Chief Operating Officer | N/A | N/A | 1967 |
Mr. Malek Chamoun | Chief Development Officer | N/A | N/A | 1985 |
Mr. Robert G. Ferreira | President of Sunshine Bio Investments Inc | N/A | N/A | 1962 |
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
Sunshine Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.